10.2 C
New York
Friday, March 29, 2024

12 Biggest Mid-Day Losers For Thursday

Courtesy of Benzinga.

  • Summit Therapeutics PLC (ADR) (NASDAQ: SMMT) shares dipped 18.7 percent to $12.40. Summit Therapeutics priced public offering of 1.459 million ADS’s at $12.00 per ADS.
  • Workhorse Group Inc (NASDAQ: WKHS) shares dropped 16 percent to $2.95. Workhorse priced its 3.75 million share common stock and warrant offering at $3.20 per share.
  • Glaukos Corp (NYSE: GKOS) shares fell 15 percent to $35.14 after the company lowered its FY2017 sales guidance.
  • Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares slipped 13.2 percent to $11.95.
  • Reven Housing Reit Inc (NASDAQ: RVEN) shares fell 10.4 percent to $6.04.
  • Hertz Global Holdings, Inc (NYSE: HTZ) dropped 10.3 percent to $21.46. Morgan Stanley downgraded Hertz Global from Equal-Weight to Underweight.
  • BiondVax Pharmaceuticals Ltd (ADR) (NASDAQ: BVXV) shares declined 9.6 percent to $6.90. BiondVax priced its 1.5 million ADS offering at $6.00 per ADS.
  • Opko Health Inc. (NASDAQ: OPK) dropped 7.1 percent to $6.01. JP Morgan downgraded OPKO Health from Overweight to Neutral and lowered the price target from $12.00 to $7.00.
  • William Lyon Homes (NYSE: WLH) fell 6.5 percent to $ 23.19. William Lyon Homes priced its 3.32 million share common stock offering via Paulson & Co.
  • Epizyme Inc (NASDAQ: EPZM) declined 5.1 percent to $15.15. Epizyme priced 9.18 million share offering at $15.25 per share.
  • Array Biopharma Inc (NASDAQ: ARRY) shares slipped 4.8 percent to $10.02. Array Biopharma reported a $175 million offering of common stock.
  • Equifax Inc. (NYSE: EFX) dropped 4.6 percent to $94.43. FTC’s spokesman Peter Kaplan confirmed that staff is probing Equifax data breach, according to Reuters.

Posted-In: Mid-Day LosersNews Movers & Shakers Intraday Update Markets Movers

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,449FansLike
396,312FollowersFollow
2,280SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x